<DOC>
	<DOCNO>NCT01665300</DOCNO>
	<brief_summary>Trastuzumab prolongs survival patient human epidermal growth factor receptor type 2-positive breast cancer . Sequential leave ventricular ( LV ) ejection fraction ( EF ) assessment mandate detect myocardial dysfunction risk heart failure treatment . Myocardial deformation image sensitive mean detect LV dysfunction , technique evaluate patient treated trastuzumab . The aim study investigate whether change tissue deformation , assess myocardial strain strain rate ( SR ) , able identify LV dysfunction earlier conventional echocardiographic measure patient treat trastuzumab .</brief_summary>
	<brief_title>Usefulness Myocardial Deformation Imaging Trastuzumab-induced Cardiotoxicity</brief_title>
	<detailed_description>The investigator prospectively evaluate whether change tissue deformation , assess myocardial strain strain rate ( SR ) identify possibility early detection LV dysfunction patient treat trastuzumab .</detailed_description>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>HER2 ( + ) breast cancer , anticipate Trastuzumab therapy Refusal inform consent Congenital heart disease Significant arrhythmia EKG Regional wall motion abnormality ( + ) echocardiography Poor sonic window</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>myocardial deformation imaging</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>